OncoMed Pharmaceuticals initiates breast cancer study with vantictumab

OncoMed Pharmaceuticals (OMED) starts a Phase 1b dose escalation trial for vantictumab (with paclitaxel) in patients with first-, second- and third-line, locally advanced or metastatic HER2 negative breast cancer.

OMED intends to initiate three Phase 1 trials of vantictumab this year. (PR)

The company is developing the drug with Bayer (BAYZF).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs